Organovo

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Organovo
Type Public
Traded as NYSE MKTONVO
Industry 3D Bioprinting
Founded 2007
Headquarters San Diego, California, USA
Website www.organovo.com

Organovo (ONVO) Holdings, Inc. is an early-stage medical laboratory and research company which designs and develops functional, three dimensional human tissue (also known as 3D bio-printing technology) for medical research and therapeutic applications. Organovo was established in 2007 and is headquartered in San Diego California. The company utilizes its NovoGen MMX Bioprinter for 3D bioprinting.

Organovo anticipates that the bioprinting of human tissues will accelerate the preclinical drug testing and discovery process, enabling treatments to be created more quickly and at lower cost. Additionally, Organovo has long-term expectations that this technology could be suitable for surgical therapy and transplantation.[1]

Corporate governance[edit]

As of 2014, the company's executive vice-president of commercial operations was Mike Renard.[2]:1

References[edit]

  1. ^ http://www.organovo.com/3d-human-tissues
  2. ^ Dyle, Ken (15 May 2014). "Bioprinting:From Patches to Parts". Gen. Eng. Biotechnol. News (paper) 34 (10): 1, 34–5.